A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback